Vital Signs - Embryonic Stem Cells: High Potential and Controversy
Vital Signs - Embryonic Stem Cells: High Potential and Controversy
RELEASE DATE
01-Dec-2008
01-Dec-2008
REGION
North America
North America
Research Code: 9561-00-7C-00-00
SKU: HC00555-NA-MR_04027
$1,500.00
In stock
SKU
HC00555-NA-MR_04027
Description
This issue of Vital Signs, released on December 1, 2008, provides an strategic overview of trends and issues surrounding embryonic stem cell development in the U.S. Additionally, a company spotlight is provided for Seattle Genetics, a biotechnology company focused on the development and commercialization of therapeutic monoclonal antibodies for the treatment of autoimmune diseases and cancer. Reimbursement and regulatory news from the FDA is also provided for the week of November 17, 2008.
Table of Contents
This week's issue:
Related Research
This issue of Vital Signs, released on December 1, 2008, provides an strategic overview of trends and issues surrounding embryonic stem cell development in the U.S. Additionally, a company spotlight is provided for Seattle Genetics, a biotechnology company focused on the development and commercialization of therapeutic monoclonal antibodies for the treatment of autoimmune diseases and cancer. Reimbursement and regulatory news from the FDA is also provided for the week of November 17, 2008.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | 9561-00-7C-00-00 |
Is Prebook | No |